Dr. Agarwal on Potential Agents for Metastatic Hormone-Sensitive Prostate Cancer

Neeraj Agarwal, MD
Published: Tuesday, Jul 11, 2017



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses potential agents for the treatment of patients with metastatic hormone-sensitive prostate cancer.

There are many other agents being tested for the treatment of patients with metastatic hormone-sensitive prostate cancer, explains Agarwal. The SWOG-1216 trial is testing TAK-700, which is similar to abiraterone acetate (Zytiga). This trial has finished accrual and, if results are positive, it can be a potential option for patients.

A novel androgen receptor-blocker, ARN-509, is another agent in an ongoing trial that could be a potential option if it shows promise, states Agarwal.
 


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses potential agents for the treatment of patients with metastatic hormone-sensitive prostate cancer.

There are many other agents being tested for the treatment of patients with metastatic hormone-sensitive prostate cancer, explains Agarwal. The SWOG-1216 trial is testing TAK-700, which is similar to abiraterone acetate (Zytiga). This trial has finished accrual and, if results are positive, it can be a potential option for patients.

A novel androgen receptor-blocker, ARN-509, is another agent in an ongoing trial that could be a potential option if it shows promise, states Agarwal.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x